Physician profile
Kelly Ciera Williams
NPI 1952015497
$2,235.85
in general payments reported to CMS, 2019-2025
15 companies · $954 in 2025
The $954 reported for 2025 was more than what 92% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $275 · 2024: $1,007 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $507.54 | 2024-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $427.09 | 2023-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $230.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.73 | 2023-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $186.06 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $170.03 | 2023-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $154.76 | 2024-2025 | |
| Mylan Specialty L.P. | $126.31 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $62.66 | 2025 | Ohtuvayre |
| Amgen INC. | $61.56 | 2024-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $29.18 | 2025 | Lumryz |
| Genentech USA, INC. | $25.28 | 2024 | Xolair |
| Alexion Pharmaceuticals, INC. | $21.68 | 2023 | Soliris |
| Axsome Therapeutics, INC. | $21.25 | 2024 | Sunosi |
| Viatris Specialty LLC | $19.86 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.